GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Tangible Book per Share

Nuvectis Pharma (Nuvectis Pharma) Tangible Book per Share : $0.76 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Nuvectis Pharma's tangible book value per share for the quarter that ended in Mar. 2024 was $0.76.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Nuvectis Pharma Tangible Book per Share Historical Data

The historical data trend for Nuvectis Pharma's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Tangible Book per Share Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
- -0.87 0.97 0.70

Nuvectis Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 1.18 0.96 0.70 0.76

Competitive Comparison of Nuvectis Pharma's Tangible Book per Share

For the Biotechnology subindustry, Nuvectis Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvectis Pharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's Price-to-Tangible-Book falls into.



Nuvectis Pharma Tangible Book per Share Calculation

Nuvectis Pharma's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(12.201-0-0)/17.4189
=0.70

Nuvectis Pharma's Tangible Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(14.022-0-0)/18.3561
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Nuvectis Pharma  (NAS:NVCT) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Nuvectis Pharma Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvectis Pharma (Nuvectis Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.
Executives
Ron Bentsur director, officer: Chairman & CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri 10 percent owner 27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu officer: Chief Science and Business Off C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh officer: Chief Development Officer C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson officer: Vice President, Finance C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Int. Principal Financial Off. C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan director C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024

Nuvectis Pharma (Nuvectis Pharma) Headlines

From GuruFocus

Nuvectis Pharma Announces FDA Clearance of IND for NXP800

By PurpleRose PurpleRose 07-11-2022

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

By sperokesalga sperokesalga 05-15-2023

Is Nuvectis Pharma Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 09-06-2022